Gilead Sciences Inc Shs Unsponsored Brazilian Depository Receipt Repr 1/2 Sh GILD34
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- R$61.81
- Day Range
- R$62.52–62.88
- 52-Week Range
- R$52.08–66.29
- Bid/Ask
- R$0.00 / R$0.00
- Shares Outstanding
- 14.88B
- Market Cap
- R$933.84B
- Volume/Avg
- 108 / 550
Key Statistics
- Price/Earnings (Normalized)
- 16.51
- Price/Sales
- 5.83
- Dividend Yield (Trailing)
- 1.59%
- Dividend Yield (Forward)
- 1.58%
- Dividend Payment Schedule
- Jan, Apr, Jul, Oct
- Total Yield
- 2.23%
Company Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 17,000
- Website
- https://www.gilead.com
Competitors
Valuation
|
Metric
|
GILD34
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.51 | 45.36 | 11.46 |
Price/Book Value | 15.22 | 8.57 | 3.98 |
Price/Sales | 5.83 | 5.43 | 2.13 |
Price/Cash Flow | 11.73 | 16.30 | 9.11 |
Price/Earnings
GILD34
MRK
GSK
Financial Strength
|
Metric
|
GILD34
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.75 | 0.71 | 0.52 |
Current Ratio | 1.27 | 1.32 | 0.82 |
Interest Coverage | −1.28 | 4.28 | 9.51 |
Quick Ratio
GILD34
MRK
GSK
Profitability
|
Metric
|
GILD34
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | −0.75% | 6.27% | 11.66% |
Return on Equity (Normalized) | −2.11% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 0.26% | 9.82% | 22.63% |
Return on Assets
GILD34
MRK
GSK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|T!Tt@>V | LOCK|$Ry | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|pVtq>> | LOCK|^! | $630B | |||
| AbbVie Inc
ABBV
| LOCK|@@>^R#v | LOCK|mf | $489B | |||
| Merck & Co Inc
MRK
| LOCK|H^&%gg | LOCK|LjD | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|T^>MY>s | LOCK|w^< | $344B | |||
| Novartis AG ADR
NVS
| LOCK|z%#n#BL# | LOCK|p&x | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|BL<v!z&? | LOCK|Ds | $246B | |||
| Amgen Inc
AMGN
| LOCK|s><#$&j | LOCK|%Kj | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|t&X?TBC | LOCK|%Zz | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|rWwd>Qq | LOCK|r@ | $169B |
United States